Focused on the development of novel and highly efficacious drugs for the treatment of inflammatory diseases
Founded in December 2017, Temisis Therapeutics (“Temisis”) is a pre-clinical biotechnology company focused on the development of novel and highly efficacious compounds for the treatment of inflammatory diseases with high unmet needs.
In ongoing pre-clinical trials, Temisis’ proprietary programs, including TEM-1657, have shown significant efficacy and a best-in-class safety profile to treat psoriasis, with none of the common side effects associated with existing topical and oral treatments.
Our proprietary and novel small-molecule pre-clinical programs, including TEM1657, have showed great efficacy, orally and topically, to remit psoriasis symptoms but without the common side effects associated with existing treatments.
Inflammatory symptoms are rapidly reduced after the first application of our lead compounds, including TEM1657, in line with existing topical and oral treatments
Complete remission of psoriasis symptoms
No erythema – Regulated desquamation – Normal skin thickness
Greater efficacy than existing oral treatments (Apremilast)
Similar efficacy than existing topical corticosteroid treatments
Best-in class safety profile
No skin thinning (unlike corticosteroids), no observed side effect on animals in toxicity tests.
No common side effects associated with existing topical and oral treatments.
19 av de la Forêt de Haye,
Tel.: +33 (0) 383 940 342